BR112022026908A2 - Inibidores de rip1k - Google Patents
Inibidores de rip1kInfo
- Publication number
- BR112022026908A2 BR112022026908A2 BR112022026908A BR112022026908A BR112022026908A2 BR 112022026908 A2 BR112022026908 A2 BR 112022026908A2 BR 112022026908 A BR112022026908 A BR 112022026908A BR 112022026908 A BR112022026908 A BR 112022026908A BR 112022026908 A2 BR112022026908 A2 BR 112022026908A2
- Authority
- BR
- Brazil
- Prior art keywords
- rip1k
- inhibitors
- inhibitor compounds
- kinase
- rip1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
INIBIDORES DE RIP1K. A presente invenção refere-se a compostos inibidores de quinase, tais como compostos inibidores de proteína quinase de interação com o receptor 1 (RIP1), bem como composições farmacêuticas e combinações compreendendo tais compostos inibidores. Os compostos, composições farmacêuticas e/ou combinações descritas podem ser usados para tratar ou prevenir uma doença ou condição associada à quinase, particularmente uma doença ou condição associada a RIP1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047194P | 2020-07-01 | 2020-07-01 | |
PCT/US2021/039112 WO2022005898A1 (en) | 2020-07-01 | 2021-06-25 | Rip1k inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022026908A2 true BR112022026908A2 (pt) | 2023-03-14 |
Family
ID=76972022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022026908A BR112022026908A2 (pt) | 2020-07-01 | 2021-06-25 | Inibidores de rip1k |
Country Status (19)
Country | Link |
---|---|
US (2) | US11667643B2 (pt) |
EP (1) | EP4175714A1 (pt) |
JP (1) | JP2023532718A (pt) |
KR (1) | KR20230033712A (pt) |
CN (1) | CN116209662A (pt) |
AR (1) | AR122703A1 (pt) |
AU (1) | AU2021300831A1 (pt) |
BR (1) | BR112022026908A2 (pt) |
CA (1) | CA3183296A1 (pt) |
CL (1) | CL2022003812A1 (pt) |
CO (1) | CO2023000051A2 (pt) |
CR (1) | CR20220685A (pt) |
DO (1) | DOP2022000300A (pt) |
EC (1) | ECSP22097749A (pt) |
IL (1) | IL299128A (pt) |
MX (1) | MX2023000138A (pt) |
PE (1) | PE20230730A1 (pt) |
TW (1) | TWI824259B (pt) |
WO (1) | WO2022005898A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
WO2023240379A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
EP3256467A1 (en) | 2015-02-13 | 2017-12-20 | GlaxoSmithKline Intellectual Property Management Limited | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
WO2017004500A1 (en) | 2015-07-02 | 2017-01-05 | Genentech, Inc. | Bicyclic lactams and methods of use thereof |
PL3362449T3 (pl) | 2015-10-13 | 2021-12-13 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową |
JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
WO2017136727A2 (en) * | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
JP7349359B2 (ja) | 2016-10-17 | 2023-09-22 | エフ. ホフマン-ラ ロシュ アーゲー | 二環式ピリドンラクタム及びその使用方法。 |
US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
WO2019134680A1 (zh) | 2018-01-05 | 2019-07-11 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
PT3788044T (pt) | 2018-05-03 | 2023-08-31 | Rigel Pharmaceuticals Inc | Compostos inibidores de rip1 e métodos para preparar e usar os mesmos |
HRP20230909T1 (hr) | 2018-05-03 | 2023-12-08 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
US20210292340A1 (en) | 2018-06-26 | 2021-09-23 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Rip1キナーゼを阻害する複素環状アミド及びその使用 |
CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
EP4025575A1 (en) | 2019-09-06 | 2022-07-13 | Rigel Pharmaceuticals, Inc. | Rip1 inhibitory compounds and methods for making and using the same |
JP7376218B2 (ja) | 2019-09-06 | 2023-11-08 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Rip1阻害化合物ならびにそれを作製および使用するための方法 |
TW202132307A (zh) | 2019-11-07 | 2021-09-01 | 美商雷傑製藥公司 | 雜環rip1抑制性化合物 |
AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
-
2021
- 2021-06-22 TW TW110122698A patent/TWI824259B/zh active
- 2021-06-22 AR ARP210101712A patent/AR122703A1/es unknown
- 2021-06-25 CA CA3183296A patent/CA3183296A1/en active Pending
- 2021-06-25 KR KR1020237003542A patent/KR20230033712A/ko active Search and Examination
- 2021-06-25 JP JP2022581403A patent/JP2023532718A/ja active Pending
- 2021-06-25 CR CR20220685A patent/CR20220685A/es unknown
- 2021-06-25 PE PE2022003090A patent/PE20230730A1/es unknown
- 2021-06-25 IL IL299128A patent/IL299128A/en unknown
- 2021-06-25 EP EP21743351.5A patent/EP4175714A1/en active Pending
- 2021-06-25 WO PCT/US2021/039112 patent/WO2022005898A1/en active Application Filing
- 2021-06-25 BR BR112022026908A patent/BR112022026908A2/pt unknown
- 2021-06-25 MX MX2023000138A patent/MX2023000138A/es unknown
- 2021-06-25 US US17/358,698 patent/US11667643B2/en active Active
- 2021-06-25 AU AU2021300831A patent/AU2021300831A1/en active Pending
- 2021-06-25 CN CN202180053850.6A patent/CN116209662A/zh active Pending
-
2022
- 2022-12-29 CL CL2022003812A patent/CL2022003812A1/es unknown
- 2022-12-29 DO DO2022000300A patent/DOP2022000300A/es unknown
- 2022-12-30 EC ECSENADI202297749A patent/ECSP22097749A/es unknown
-
2023
- 2023-01-04 CO CONC2023/0000051A patent/CO2023000051A2/es unknown
- 2023-04-26 US US18/307,181 patent/US20230265100A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202214225A (zh) | 2022-04-16 |
MX2023000138A (es) | 2023-04-11 |
IL299128A (en) | 2023-02-01 |
CN116209662A (zh) | 2023-06-02 |
TW202408480A (zh) | 2024-03-01 |
JP2023532718A (ja) | 2023-07-31 |
DOP2022000300A (es) | 2023-03-31 |
AR122703A1 (es) | 2022-09-28 |
CR20220685A (es) | 2023-03-28 |
ECSP22097749A (es) | 2023-03-31 |
US20220009936A1 (en) | 2022-01-13 |
WO2022005898A1 (en) | 2022-01-06 |
TWI824259B (zh) | 2023-12-01 |
US11667643B2 (en) | 2023-06-06 |
US20230265100A1 (en) | 2023-08-24 |
CO2023000051A2 (es) | 2023-04-17 |
EP4175714A1 (en) | 2023-05-10 |
AU2021300831A1 (en) | 2023-01-19 |
PE20230730A1 (es) | 2023-05-03 |
CA3183296A1 (en) | 2022-01-06 |
KR20230033712A (ko) | 2023-03-08 |
CL2022003812A1 (es) | 2023-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022019492A2 (pt) | Inibidores de rip1k | |
BR112022002581A2 (pt) | Inibidores heterocíclicos de rip1 quinase | |
BR112022002378A2 (pt) | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos | |
CO2020015156A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos referencia cruzada a una solicitud relacionada | |
CY1126152T1 (el) | Ενωσεις-αναστολεις της rip1 και μεθοδοι παρασκευης και χρησης αυτων | |
BR112022002698A2 (pt) | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 | |
BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
BR112022026908A2 (pt) | Inibidores de rip1k | |
BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
BR112023018167A2 (pt) | Compostos inibidores heterocíclicos de rip1 quinase, composições farmacêuticas e composições que os compreendem, e usos dos mesmos | |
AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
BR112022025191A2 (pt) | Compostos de imidazopiridazina com atividade de inibidores de alk2 |